v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following table illustrates our segment information for significant operating expenses and includes a reconciliation to net loss for the three months ended March 31, 2026 and 2025:
 Three Months Ended March 31
 20262025
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial$(50)$788 
  ASCEND trial174 21 
  Chemistry, manufacturing and controls191 220 
  Clinical department768 1,156 
  Other (1)
121 417 
Research and development1,204 2,602 
General and administrative by significant expense:
  Corporate1,333 1,144 
  Investor relations/public relations/communications237 331 
  Finance585 629 
  Legal1,094 224 
  Business development149 127 
  Share based compensation expense293 404 
  Other (2)
47 386 
General and administrative3,738 3,245 
Operating loss(4,942)(5,847)
Other income, net66 161 
Benefit from income taxes(387)(962)
Net loss$(4,489)$(4,724)
Cash and marketable securities$13,060 $25,833 
 (1) Included in Other are the GBM study, FORTIFIDE study and research
     oncology expenses
 (2) Included in Other are facilities expense, human resource
     and information technology expenses